A Qureishi1, M Ali2, L Fraser3, K A Shah4, H Møller5, S Winter3. 1. Specialist Registrar, Department of Otolaryngology, Oxford University Hospitals NHS Trust, Oxford, UK. 2. Department of Molecular Diagnostics, Oxford University Hospitals NHS Trust, Oxford, UK. 3. Consultant Head and Neck Surgeon, Department of Otolaryngology, Oxford University Hospitals NHS Trust, Oxford, UK. 4. Consultant Head and Neck Pathologist, Department of Histopathology, Oxford University Hospitals NHS Trust, Oxford, UK. 5. Head of Cancer Epidemiology and Population Health, Kings College London, London, UK.
Abstract
BACKGROUND: New cases of oropharyngeal squamous cell carcinoma (OPSCC) are routinely tested for HPV. HPV in saliva can be detected with PCR, but its clinical applicability in the context of OPSCC remains unknown. METHODS: Forty-six consecutive patients diagnosed with OPSCC had pre-treatment saliva specimens collected. PCR for HPV on saliva was compared to p16 IHC and HPV DNA in situ hybridisation (ISH) on surgical biopsies. RESULTS: The sensitivity and specificity of saliva testing when compared to the reference test of p16 IHC and HPV DNA ISH were 72.2% and 90%, and positive and negative predictive values were 96.3% and 47.4%. There were no adverse events. Time from last meal, smoking, alcohol drinking and physical exercise did not impact on results. CONCLUSIONS: Saliva testing is a promising test to detect HPV in patients with OPSCC. A positive result could avoid the need for surgical biopsies, thereby reducing costs, patient morbidity and expedite treatment.
BACKGROUND: New cases of oropharyngeal squamous cell carcinoma (OPSCC) are routinely tested for HPV. HPV in saliva can be detected with PCR, but its clinical applicability in the context of OPSCC remains unknown. METHODS: Forty-six consecutive patients diagnosed with OPSCC had pre-treatment saliva specimens collected. PCR for HPV on saliva was compared to p16 IHC and HPV DNA in situ hybridisation (ISH) on surgical biopsies. RESULTS: The sensitivity and specificity of saliva testing when compared to the reference test of p16 IHC and HPV DNA ISH were 72.2% and 90%, and positive and negative predictive values were 96.3% and 47.4%. There were no adverse events. Time from last meal, smoking, alcohol drinking and physical exercise did not impact on results. CONCLUSIONS: Saliva testing is a promising test to detect HPV in patients with OPSCC. A positive result could avoid the need for surgical biopsies, thereby reducing costs, patient morbidity and expedite treatment.
Authors: Yuki Saito; Alexander V Favorov; Michael Forman; Shuling Ren; Akihiro Sakai; Takahito Fukusumi; Chao Liu; Sayed Sadat; Mizuo Ando; Guorong Xu; Zubair Khan; John Pang; Alex Valsamakis; Kathleen M Fisch; Joseph A Califano Journal: Head Neck Date: 2019-12-18 Impact factor: 3.147
Authors: Kai Dun Tang; Lilian Menezes; Kurt Baeten; Laurence J Walsh; Bernard C S Whitfield; Martin D Batstone; Liz Kenny; Ian H Frazer; Gert C Scheper; Chamindie Punyadeera Journal: Biomolecules Date: 2020-02-03
Authors: Kathrine Kronberg Jakobsen; Amanda-Louise Fenger Carlander; Simone Kloch Bendtsen; Martin Garset-Zamani; Charlotte Duch Lynggaard; Christian Grønhøj; Christian von Buchwald Journal: Viruses Date: 2021-08-26 Impact factor: 5.048